Cargando…

Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas

BACKGROUND: CD70 has been regarded as a novel potential therapeutic target for multiple cancers. In this study, we characterized the expression of the CD70 protein in ovarian carcinomas and assessed its clinical-pathological prognostic value. MATERIALS AND METHODS: The expression of CD70 in advanced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Naifu, Sheng, Xiugui, Liu, Yi, Zhang, Xiaoling, Yu, Jinming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681401/ https://www.ncbi.nlm.nih.gov/pubmed/23776334 http://dx.doi.org/10.2147/OTT.S44445

Ejemplares similares

Effects of sequential paclitaxel–carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study
por: Wang, Fei, et al.
Publicado: (2016)

Wilms’ Tumor 1-Associated Protein Contributes to Chemo-Resistance to Cisplatin Through the Wnt/β-Catenin Pathway in Endometrial Cancer
por: Xie, Wenli, et al.
Publicado: (2021)

Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature
por: Serkies, Krystyna, et al.
Publicado: (2011)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Derlin1 functions as an oncogene in cervical cancer via AKT/mTOR signaling pathway
por: Li, Ling, et al.
Publicado: (2019)

Deregulation of Exo70 Facilitates Innate and Acquired Cisplatin Resistance in Epithelial Ovarian Cancer by Promoting Cisplatin Efflux
por: Zhao, Yujie, et al.
Publicado: (2021)

Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer.
por: Green, J. A., et al.
Publicado: (1988)

Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.
por: Fosså, S. D., et al.
Publicado: (1996)

Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced‐stage ovarian cancer
por: Huang, Chueh‐Yi, et al.
Publicado: (2020)

Dose-Intense Cisplatin-Based Neoadjuvant Chemotherapy Increases Survival in Advanced Cervical Cancer: An Up-to-Date Meta-Analysis
por: Nguyen, Van Tai, et al.
Publicado: (2022)

CD70: A Potential Target in Breast Cancer?
por: Petrau, Camille, et al.
Publicado: (2014)

Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan
por: Nouso, K, et al.
Publicado: (2013)

Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
por: Kim, Myung Joo, et al.
Publicado: (2012)

Variant-beta luteinizing hormone is not associated with poor ovarian response to controlled ovarian hyperstimulation
por: Hanevik, Hans I, et al.
Publicado: (2014)

Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study
por: Coccolini, Federico, et al.
Publicado: (2015)

Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer
por: Yeon, Sang Hoon, et al.
Publicado: (2023)

Hyperthermic intrathoracic chemotherapy with cisplatin for ovarian cancer with pleural metastasis
por: Jun, Su Youn, et al.
Publicado: (2017)

Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells
por: Chun, Jaemoo
Publicado: (2023)

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
por: Polee, M B, et al.
Publicado: (2003)

Nuclear morphology predicts cell survival to cisplatin chemotherapy
por: Kim, Chi-Ju, et al.
Publicado: (2023)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
por: Baruah, Upasana, et al.
Publicado: (2015)

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells
por: Huang, Ming-ju, et al.
Publicado: (2018)

Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
por: Lee, Myung-Won, et al.
Publicado: (2020)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer
por: Glennon, Kate, et al.
Publicado: (2021)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
por: Inoue, Hiroto, et al.
Publicado: (2021)

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman Andrés, et al.
Publicado: (2017)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis
por: Liu, Yuexi, et al.
Publicado: (2023)

Clinicopathologic factors associated with short-term survival in advanced epithelial ovarian cancer
por: Zhou, Shuwei, et al.
Publicado: (2019)

The HSP70 gene predicts prognosis and response to chemotherapy in epithelial ovarian cancer
por: Li, Xiao-Fei, et al.
Publicado: (2021)

Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients
por: He, Ling, et al.
Publicado: (2013)

Association between cumulative cisplatin dose and reproductive and sexual functions in patients with malignant ovarian germ cell tumors treated with bleomycin, etoposide, and cisplatin therapy: a case series study
por: Akasaka, Miki, et al.
Publicado: (2022)

Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma
por: Ma, Ming-Chun, et al.
Publicado: (2014)

Luteal phase ovarian stimulation following oocyte retrieval: is it helpful for poor responders?
por: Zhang, John
Publicado: (2015)

MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer
por: Ko, Jihoon, et al.
Publicado: (2022)

Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer
por: Yoon, Ji-Young, et al.
Publicado: (2014)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8cljtsc0f96dnf7pll0irifj9b